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Background: Both diabetes and glucose-lowering medications have been associated with an increased risk of
cancer incidence. This study will compare cancer incidence rates in individuals with and without diabetes; and will
investigate, in individuals with diabetes, an association between glucose control and cancer incidence; and
between the use of specific glucose-lowering medications, as well as no drug exposure, and cancer incidence.
Methods/design: This is a population based historical cohort study of all individuals aged 21 years or older (about
2,300,000) who were insured by Clalit Health Services, the largest health maintenance organization in Israel during a
ten-year study period. Four study groups will be established according to the status of diabetes and cancer at study
entry, Jan 1, 2002: cancer free, diabetes free; cancer free, diabetes prevalent; cancer prevalent, diabetes free; and cancer
prevalent, diabetes prevalent. Individuals without diabetes at study entry will be followed for diabetes incidence, and all
four groups will be followed for specific cancer incidence, including second primary neoplasms. Glucose control will be
assessed by HbA1c and by fasting plasma glucose levels. Time dependent regression models for cancer incidence will
account for glucose-lowering medications as they are added and changed over the follow-up period. A large number
of demographic and clinical variables will be considered, including: age, gender, BMI, smoking status, concomitant
medications, glucose control (assessed by HbA1c and by fasting plasma glucose) and cancer screening tests.
Discussion: Strengths of this study include the large population; high quality comprehensive data; comparison to
individuals without diabetes, and to those with diabetes but not treated with glucose-lowering medications; and the
extensive range of variables available for analysis. The great increases in diabetes prevalence and in treatment options
render this study particularly relevant and timely. The Israeli national healthcare system, characterized by high standard
and uniform healthcare, offers an advantageous environment for its conduct.
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This study responds to a number of recent trends: the
increasing prevalence of diabetes, the accumulating evi-
dence of the relationship between diabetes and cancer
[1] and the increasing number of options available for
treating diabetes. The overall aim is to elucidate the* Correspondence: racheld@gertner.health.gov.il
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reproduction in any medium, provided the orrelationship between diabetes and cancer incidence
(overall and specific cancers, including second primary
neoplasms). Specifically, this is a ten year nationwide
population-based investigation of the associations of
cancer incidence with diabetes, glucose control and
glucose-lowering medications.
To the best of our knowledge, a relationship between
glucose control and cancer has not yet been examined.
Since glucose control has been found to associate with
both micro- and macrovascular complications of dia-
betes, and cancer is now considered a complication of
diabetes, investigation of the effect of glucose control on
cancer risk is relevant. Further, data on glucose controll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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medications, since initiation of treatment and switching
between treatments may be related to patients’ glucose
control.
The use of glucose-lowering medications has been
associated with cancer incidence. Sulfonylureas and
injected insulin have been found to associate positively
with cancer risk [2-5]; and metformin, which improves
insulin sensitivity and lowers insulin levels, to be asso-
ciated negatively with cancer risk, and to possibly have
a protective role [2-7]. A number of studies reported
elevated incidence of malignancy following the use of
insulin glargine [8-10], though their methodologies
have been seriously challenged [11-14]. In particular,
the Hemkens et al. study [9] was widely criticized [15-17]
for not considering such factors as current health sta-
tus, type of diabetes, intensity of glucose lowering treat-
ment, concomitant medications, BMI, glucose control
(HbA1c), hormone replacement therapy, smoking sta-
tus, and cancer screening. More recently, others have
tried to overcome biases by comparing glargine to
human insulin, while excluding other insulin analogs
[18], or by including only individuals with type 2 dia-
betes [19]. Nevertheless, those studies were criticized
for short follow-up periods. Siussa et al. [20] showed
how long-term follow-up, of up to 8 years, helped dis-
tinguish between possible mechanisms for the associ-
ation between glargine use and an increased risk of
cancer. The proposed study, with 10 year follow-up, will
assess oral glucose lowering medications, as well as insulin.
We expect to reveal differential effects of glucose-lowering
medications on site-specific cancer in one large population
cohort.
Methods/design
This is a large scale historical cohort study of all adult
individuals insured by Clalit Health Services, the largest
health maintenance organization in Israel, insuring and
providing healthcare to 55% of the Israeli population
(about 3.9 million people). Study entry is defined as
January 1, 2002. Inclusion criteria will be: age 21 years
or older at study entry and continuous insurance in
Clalit Health Services from at least one year prior to
study entry, January 1 2001, until the end of the study
period, December 31, 2011, or until death, for those
who do not survive until the end of follow-up. Of the
population of over 2,300,000, over 110,000 had dia-
betes at study entry; and an additional 350,000 were
diagnosed with diabetes during the study period (Janu-
ary 2002 to December 2011).
This study has three Specific Aims: First, we will com-
pare rates of cancer incidence (overall and specific can-
cers, including second primary neoplasms) in individuals
with and without diabetes (separately for prevalent andincident cases of diabetes). Second, we will investigate,
in individuals with diabetes, the associations between
measures of glucose control, as assessed by HbA1c and
fasting plasma glucose, and cancer incidence (overall
and specific cancers, including second primary neo-
plasms). Third, we will compare the incidence of can-
cer (overall and specific cancers, including second
primary neoplasms), among individuals with diabetes
who used specific glucose-lowering medications, as
well as among patients with no drug exposure (periods
of time during which individuals classified with dia-
betes did not yet purchase glucose-lowering medica-
tions, including periods on diet and exercise regimen
only).
Four study groups will be established according to the
status of diabetes and cancer at study entry, Jan 1, 2002
(Figure 1): cancer free, diabetes free (CF-DF); cancer
free, diabetes prevalent (CF-DP); cancer prevalent, dia-
betes free (CP-DF); and cancer prevalent, diabetes preva-
lent (CP-DP). Individuals free of diabetes at study entry
will be followed for diabetes incidence, and all four
groups will be followed for cancer incidence (second pri-
maries for those with prevalent cancer). Nine groups,
according to diabetes and cancer prevalence at study
entry, and diabetes and cancer and incidence during the
study period, will be analyzed (Figure 2).
Diabetes classification
Prevalent diabetes was determined according to phys-
ician reports to the chronic disease registry of Clalit
Health Services. Incident diabetes will be determined
by any one of the following criteria: two fasting glu-
cose readings of 126 mg/dl or above during the course
of a year, HbA1c greater than 7.0%, 3 recorded pur-
chases of glucose-lowering medications during the
course of a year, diagnosis of diabetes according to
the Chronic Disease Registry of Clalit Health Services,
or a written diagnosis by a physician (in the commu-
nity or hospital). The relatively low number of indivi-
duals classified with diabetes at study entry (prevalent
diabetes) is apparently due to the more limited defin-
ition of diabetes used by Clalit Health Services prior
to 2002.
Exposure to glucose-lowering medications
In addition to the exposure to diabetes per se, indivi-
duals with diabetes will be studied for their exposure to
glucose-lowering medications. A drug exposure will be
defined as a minimum of 3 purchases of glucose-
lowering medications during one year. Each drug expos-
ure will define one type of treatment or a combination
of treatments. An individual may be analyzed according
to more than one exposure during follow-up time. Drug



















Figure 1 The ten year follow-up of the four study groups, according to disease status at study entry: diabetes free (DF) or prevalent
(DP), and cancer free (CF) or prevalent (CP). For the groups that are DF at study entry, diabetes incidence (DI) will be followed and associated
with outcomes (green arrows pointing down). For the groups that are DP at study entry, glucose control and diabetes medications will be
followed and associated with the outcomes (green arrows pointing to the right). All four groups will be followed for the study outcome: overall
and specific cancers, including second primary neoplasms.
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glucosidase inhibitors, thiazolidinediones, and incretins.
An additional group (“no glucose-lowering medication”)
will comprise periods of time during which individuals
classified with diabetes did not yet purchase glucose-
lowering medications.
For each glucose-lowering medication, cumulative ex-
posure will be assessed as the total number of monthly
dosages purchased. Daily dosages and daily dosages per
body weight will be estimated from records of purchases.
Time dependent regression models for the outcomes
investigated will account for glucose-lowering medications
as they are added and changed over the follow up period,











Figure 2 The study cohort according to diabetes and cancer status du
DI - incident diabetes; DF - diabetes free; CP: prevalent cancer; CI - incidenPotential confounders
The following variables will be included together with
the time they were recorded:
1. Age, gender, BMI, type of medical insurance (basic,
or basic and supplementary).
2. Smoking status (non-smoker, former smoker,
current smoker)
3. Concomitant medications (types, exposure rates,
and cumulative exposures), including
antihypertensive, lipid lowering, beta-blockers,
angiotensin converting enzyme (ACE) inhibitors
4. Comorbidities defined according to the Clalit











ring the ten year follow-up period. DP - prevalent diabetes;
t cancer; CF - cancer free.
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gallstones)
5. Blood pressure (mean annual values)
6. Reproductive factors: hormone replacement
therapy, fertility treatments
7. Biochemical characteristics (first and last tests
during follow-up, mean annual values, and number
of blood tests performed annually): serum lipids
(total cholesterol, triglycerides, HDL-cholesterol,
VLDL-cholesterol), liver enzymes, creatinine, and
urine protein
8. Clinical examinations (average annual number of
visits to the treating physician during follow-up)
9. Cancer screening tests: mammography, fecal occult
blood, colonoscopy, PAP smear, colposcopy,
prostate screening (PSA, ultrasound)
10. Medical procedures associated with cancer risk (e.g.
cholecystectomy).
We note that data on some key potential confounders
(like smoking and fertility treatments) are available for
only a subset of the cohort. We will conduct sensitivity
analyses in these subsets to assess whether these factors
indeed confound the associations between diabetes,
glucose-lowering medications, and cancer.
Outcomes
Incidence of cancer (both first and second primary neo-
plasms) will be the primary outcome. For diagnoses of
cancer, the following data from the Israel National Can-
cer Registry will be linked to the study file: date of diag-
nosis; place of diagnosis; hospital or other reporting
source; disease type, site, morphology, and stage at diag-
nosis; tumor behavior (in-situ, benign, malignant, bor-
derline, and uncertain); basis of diagnosis (pathology
report, clinical only, imaging devices, or based on death
certificates only); and mortality data. Mortality data is
continuously updated by reports from the Ministry for
Internal Affairs.
Data management
A database will be constructed for the proposed study
from the Clalit Health Services data warehouse. Avail-
able are demographic data and vital status from the Is-
raeli Ministry of Interior Affairs and the National
Insurance Institute (Social Security); drug dispensing
data from pharmacies; and medical data such as labora-
tory tests, imaging results, diagnoses and clinical data
(blood pressure, weight, height, etc.) from Clalit Health
Services in-house facilities, as well as from outside sup-
pliers. The data are accessible at the member level, and
linked to all registries, including the Cancer Registry, by
means of a national identification number, a unique
identifier possessed by all Israeli citizens. Data will beorganized according to the BI (business intelligence)
schema or infrastructure and are extracted using BI pro-
grams. Extraction is executed via the BO (business ob-
ject) and SQL server management studio programs,
depending on the complexity and diversity of the data
requested from the data warehouse. BI analyst specialists
will conduct the extraction and merge the data.
Power calculation
The most conservative estimates yield at least 175,000
incident cases of cancer in the total cohort. Thus, ad-
equate power is expected for a large number of cancer
types and treatment regimens. The sample size for ana-
lysis will decrease as the number of treatment switches
increases and as certain combinations become rare.
Nevertheless, power will be adequate to find relatively
small differences based even on subsets of 500–1000
events for a particular treatment or treatment combin-
ation. Specifically, we will have over 80% power (based
on two-tailed testing at the 0.05 level) to detect a hazard
ratio of 1.4 for two subsets of 6000 persons each.
Statistical analyses
For our first specific aim, we will compare, after adjust-
ment, all and site-specific cancer rates between indivi-
duals with and without diabetes. For the second aim, we
will investigate whether metabolic control, as indicated
by HbA1c and blood glucose levels, is related to cancer
risk. Third, we will evaluate differences in outcomes that
associate with the use of one or a combination of
glucose-lowering treatments. In all of these analyses we
will stratify persons with diabetes by those who were
already diagnosed with diabetes at study entry (prevalent
diabetes), and those who were diagnosed during follow-
up (incident diabetes).
Preliminary data analysis will employ standard meth-
ods, starting with calculation of person years and age-
gender standardized cancer incidence rates for all sites
and selected sites in non-diabetics, and in prevalent and
incident diabetics without prevalent cancer. These meth-
ods will also be used to investigate potential confound-
ing variables such as baseline smoking status and body
mass index. In our analyses of Specific Aims 2 and 3, we
will then proceed to use Cox regression with time-
dependent treatment variables. For Specific Aim 2, the
model will include current and past levels of Hba1c and
blood glucose, investigating the level above selected
thresholds cumulated over the past n years, where n
may be between 1 and 5. For Specific Aim 3 the model
will include current and previous treatments. For ex-
ample, we will investigate exposure to a specific medica-
tion when expressed by the cumulative dose or by the
cumulative dose over the past 1–5 years. We will investi-
gate exposure to multiple medications, first by models
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cer incidence rates (no interaction model); and if there
are sufficient data, we will proceed to examine interac-
tions between medications on cancer incidence. Due to
data limitations, it is unlikely that anything more than
pairwise interactions will be able to be examined satis-
factorily. The analyses of glucose-lowering medications
will take into account the clinical factors (HbA1c, fasting
glucose) that may have triggered the change. We will,
for example, use the methods of Walker, White, and
Babiker [21] to better evaluate how HbA1c triggers
treatment changes. This may or may not be important
for cancer incidence analyses, depending on whether
HbA1c and fasting plasma glucose are or are not related
to cancer incidence (see Specific Aim 2). In analyses of
Specific Aims 2 and 3, we will also be cautious of the
possibility of reverse causation, whereby early physio-
logical changes before the diagnosis of cancer may cause
deterioration in glucose control and subsequent change
in diabetes treatment. We will therefore investigate
whether early peaks in cancer incidence rates follow a
change in treatment, and will examine model results
when all cancer diagnoses are moved backwards in time
by a set period of 2 years, 1 year, or 6 months.
As outlined above, in specific analyses, multiple inde-
pendent sensitivity analyses will be used more gener-
ally to test our model assumptions and the robustness
of our results. We will look at varying time intervals
for the piecewise exponential models, stratification for
departures from proportional hazards, interactions and
time-dependent models including lagged predictors.
Propensity scores will be used as an alternative to direct
confounder adjustment, to control for confounding by
indication, and to check the robustness of conclusions.
We will also explore results obtained by applying the
recently described “prior event rate ratio” method of
Tannen, Weiner, and Xie [22], to the analysis of glucose-
lowering medications. Though this method will only be
applicable to incident cases of diabetes, its effectiveness
in controlling for confounding by indication has been
reported.
Cancer prevalent cases will be analyzed separately and
will have separate adjustments performed, including sep-
arate propensity scoring. This is to overcome potential
confounding factors associated with cancer treatments
and their residual effects. Furthermore, the risk of sec-
ond primary neoplasms has not been analyzed in dia-
betes patients, and might have a different pattern of
associations with the disease itself and with the use of
glucose-lowering therapies than does the risk of first
primaries.
The primary analysis will be performed using PROC
PHREG of SAS version 9.2, which allows both Cox-
proportional hazards models with time-dependentvariables and piecewise exponential models. The piece-
wise exponential model divides time-at-risk into a set
of pre-specified intervals with constant baseline hazard
in each interval; the use of multiple intervals allows the
hazard to vary with time. Clinically important time
dependent covariates for the regression models include
age, cholesterol (total, LDL, and HDL), concomitant
medications (such as statins, beta-blockers, angiotensin
converting enzyme inhibitors, and hormone replace-
ment therapy), smoking, body mass index, blood pres-
sure, co-morbidities (such as cardiovascular disease),
and reproductive history. For each continuous variable,
we will investigate appropriate transformations and
interactions that might improve goodness-of-fit. The
proportional hazard assumption will be evaluated using
log-log survival plots, examination of Schoenfeld resi-
duals, and testing of interactions between variables and
time.
While we can not describe, or even anticipate, every
contingency for this comprehensive project, we are
confident that the very well qualified team has the ex-
pertise to evaluate the data.
This study was approved by the ethics committees of
Sheba Medical Center, Tel Hashomer and Clalit Health
Services, Israel.
Discussion
Though randomized controlled trials (RCTs) are consid-
ered the gold standard for medical research, large long-
term RCTs on the relationship between diabetes and
cancer incidence are not feasible (due to high costs and
resources), may not be the best way to achieve relevant
results (due to the time required, low number of events,
and sample selection bias), and are subject to ethical
problems (by randomly allocating to treatment groups).
Specifically, now that the American College of Physi-
cians (ACP) (February 2012) [23] has strongly recom-
mended monotherapy with metformin as first-line oral
therapy for type 2 diabetes, the conduct of RCTs com-
paring monotherapy glucose-lowering medications, ie.
comparing metformin with other oral therapies, would
seem unethical.
The advantages of studies based on health insurance
administrative databases have become recognized over
recent years [24,25]. Moreover, historical cohort studies
afford timely and ethical means of comparing effects of
glucose-lowering medications, albeit with methodo-
logical challenges. Recently, a nested case control [26]
and cross-sectional study [7] adjusted for a number of
confounding variables before concluding that metformin
has a protective effect on cancer outcomes. However,
those investigations did not compare the diabetes
patients to a non-diabetic population, nor analyze by
cancer type. Currie et al., on the other hand, recently
Dankner et al. BMC Cancer 2012, 12:364 Page 6 of 7
http://www.biomedcentral.com/1471-2407/12/364reported decreased mortality among cancer patients
using metformin, even compared to those without dia-
betes, and increased survival among metformin users for
most cancer sites, but not for breast cancer [27]. The
fact that increased breast cancer was also reported
among insulin users, compared to other cancer types
[19,28], suggests that such differences may be due to
confounding factors rather than to the effects of medica-
tions. Most studies did not account for surveillance bias,
ie. the possibility that the detection of cancer may differ
between those with and without diabetes, resulting in a
spurious difference in cancer incidence between the two
groups. The observation that women with diabetes were
found to screen less for cancer than women without
[29,30] highlights the importance of mitigating surveil-
lance bias.
The current study will undertake various means to
deal with the challenges posed by recent investigations,
including comparison to a large population of indivi-
duals without diabetes in a nationwide population, and
accessing a large number of potentially confounding fac-
tors and data on cancer screening.
Statistical power is expected for a number of mono-
therapies and combination treatments among individuals
newly diagnosed with diabetes, thereby controlling for
the duration of diabetes and for all glucose-lowering
medications used during the course of their treatment.
Temporal relationships between diabetes and cancer will
be considered. A number of aspects of the study design
are expected to elucidate the complex relationship be-
tween diabetes and cancer, and possible effects of
glucose-lowering medications: analysis of data preceding
diabetes incidence, the inclusion of “no glucose-lowering
medications” as an exposure, and the inclusion of all
individuals with and without diabetes who were insured
by one very large health maintenance organization dur-
ing a ten year period.
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